Geoffrey M. Parker - 16 Oct 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/Earl Douglas, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
16 Oct 2023
Net transactions value
$0
Form type
4
Filing time
17 Oct 2023, 17:02:27 UTC
Previous filing
31 Jul 2023
Next filing
20 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +400,000 $0.000000 400,000 16 Oct 2023 Direct
transaction ALLO Common Stock Award $0 +390,000 +98% $0.000000 790,000 16 Oct 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Award $0 +950,000 $0.000000 950,000 16 Oct 2023 Common Stock 950,000 $3.24 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitutes Performance Restricted Stock Units ("PRSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each PRSU upon vesting, 50% shall vest in the event the Company achieves a 30-day weighted average share price of $18 on or before March 22, 2026 and 50% shall vest upon the first marketing approval of a Company product by the US FDA on or before March 22, 2028.
F2 25% of the shares subject to the stock option shall vest on October 16, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.